Home » Market News » DirectorsTalk Highlights » More detail on the SARS-CoV-2 ELISA laboratory test
Avacta Group Plc

More detail on the SARS-CoV-2 ELISA laboratory test

Alastair Smith gives more detail on their latest announcement that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19.

Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.